

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Condensed Interim Consolidated Financial Statements (Unaudited)**  
**30 June 2023**

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**

---

	<u>Pages</u>
- Report on review of condensed interim consolidated financial statements	2
- Interim consolidated statement of financial position	3
- Interim consolidated statement of profit or loss	4
- Interim consolidated statement of comprehensive income	5
- Interim consolidated statement of changes in equity	6
- Interim consolidated statement of cash flows	7
- Notes to the condensed interim consolidated financial statements	8 - 10



**Report on Review of Condensed Interim Consolidated Financial Statements**

**To The Board of Directors  
The Arab Pesticides & Veterinary Drugs Mfg. Co.  
Public Shareholding Company  
Irbid - Jordan**

**Introduction**

We have reviewed the accompanying condensed interim consolidated financial statements of **The Arab Pesticides & Veterinary Drugs Mfg. Co. PLC**, comprising the interim consolidated statement of financial position as at 30 June 2023 and the related interim consolidated statement of profit or loss, interim consolidated statement of comprehensive income, interim consolidated statement of changes in equity and interim consolidated statement of cash flows for the six-months period then ended and the notes about condensed interim consolidated financial statements. Management is responsible for the preparation and presentation of this condensed interim consolidated financial statement in accordance with International Accounting Standard number (34) "Interim Financial Reporting". Our responsibility is to express a conclusion on this condensed interim consolidated financial statements based on our review.

**Scope of Review**

We conducted our review in accordance with the International Standard on Review Engagements number (2410) "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of condensed interim consolidated financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim consolidated financial statement is not prepared, in all material respects, in accordance with International Accounting Standard number (34) "Interim Financial Reporting".

26 July 2023  
Amman - Jordan



**Arab Professionals**  
**Amin Samara**  
**License No. (481)**

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Financial Position as at 30 June 2023**  
**(In Jordanian Dinar)**

	Note	30 June 2023 (Unaudited)	31 December 2022 (Audited)
<b>Assets</b>			
<b>Non - current assets</b>			
Property, plant and equipment		7,719,368	7,665,319
Project under construction		1,274,717	80,813
Investment in associates		500,849	474,418
Financial assets at fair value through other comprehensive income		237,090	237,090
Check under collection – long term		110,000	20,000
<b>Total non - current assets</b>		<u>9,842,024</u>	<u>8,477,640</u>
<b>Current assets</b>			
Inventories		14,755,295	15,307,339
Other current assets		1,309,065	1,077,020
Accounts receivable		13,774,835	10,834,009
Checks under collection		2,020,062	1,887,232
Cash and cash equivalents		2,102,576	4,009,268
<b>Total current assets</b>		<u>33,961,833</u>	<u>33,114,868</u>
<b>Total assets</b>		<u><b>43,803,857</b></u>	<u><b>41,592,508</b></u>
<b>Equity and liabilities</b>			
<b>Equity</b>	4		
Paid - in capital		15,000,000	15,000,000
Statutory reserve		3,750,000	3,750,000
Voluntary reserve		2,118,949	2,118,949
Changes in foreign exchange rate		(2,796,011)	(2,772,950)
Retained earnings		9,833,709	8,725,596
<b>Total Shareholder's Equity</b>		<u>27,906,647</u>	<u>26,821,595</u>
Non-controlling interest		6,907,619	6,312,602
<b>Total equity</b>		<u>34,814,266</u>	<u>33,134,197</u>
<b>Liabilities</b>			
<b>Non - current liabilities</b>			
Notes payable – long term		88,935	167,745
Bank facilities – long term		1,130,747	893,429
Postdated checks – long term		175,854	246,198
<b>Total non - current liabilities</b>		<u>1,395,536</u>	<u>1,307,372</u>
<b>Current liabilities</b>			
Accounts payable		1,834,538	2,291,075
Bank facilities – short term		2,664,989	1,976,761
Notes payable – short term		1,426,498	1,053,386
Postdated checks – short term		345,758	259,780
Other liabilities		1,322,272	1,569,937
<b>Total current liabilities</b>		<u>7,594,055</u>	<u>7,150,939</u>
<b>Total liabilities</b>		<u>8,989,591</u>	<u>8,458,311</u>
<b>Total equity and liabilities</b>		<u><b>43,803,857</b></u>	<u><b>41,592,508</b></u>

“The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report”

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Profit or Loss**  
**For the Six Months Ended at 30 June 2023 (Unaudited)**

(In Jordanian Dinar)

	Note	For the three months ended		For the six months ended	
		30 June 2023	30 June 2022	30 June 2023	30 June 2022
Net sales		7,509,687	7,154,279	15,047,517	12,749,658
Cost of sales		(5,076,527)	(4,775,512)	(10,146,150)	(8,262,211)
<b>Gross profit</b>		<b>2,433,160</b>	<b>2,378,767</b>	<b>4,901,367</b>	<b>4,487,447</b>
Share of profit from the associate company results		95,492	82,140	165,187	141,423
Selling and distribution expenses		(214,205)	(200,218)	(461,063)	(393,645)
Administrative expenses		(503,065)	(415,847)	(928,134)	(810,581)
Financing cost		(68,086)	(53,970)	(137,105)	(100,471)
Provision for expected credit loss		-	(100,000)	(50,000)	(200,000)
Other income		1,861	27,495	42,560	27,495
<b>Profit before income tax for the period</b>		<b>1,745,157</b>	<b>1,718,367</b>	<b>3,532,812</b>	<b>3,151,668</b>
Income and National contribution tax for the period	3	(141,678)	(106,675)	(244,182)	(218,093)
<b>Profit for the period</b>		<b>1,603,479</b>	<b>1,611,692</b>	<b>3,288,630</b>	<b>2,933,575</b>
<b>Attributable to:</b>					
Shareholders of the Company		1,266,406	1,372,913	2,608,113	2,524,349
Non-controlling interest		337,073	238,779	680,517	409,226
		<b>1,603,479</b>	<b>1,611,692</b>	<b>3,288,630</b>	<b>2,933,575</b>
 <b>Basic and diluted earnings per share attributable to the shareholders</b>		 <b>0.084</b>	 <b>0.092</b>	 <b>0.174</b>	 <b>0.168</b>

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Comprehensive Income**  
**For the Six Months Ended at 30 June 2023 (Unaudited)**

(In Jordanian Dinar)

	For the three months ended		For the six months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
Profit for the period	1,603,479	1,611,692	3,288,630	2,933,575
<b>Other comprehensive income item:</b>				
Changes in foreign exchange rate	69,695	-	(23,061)	(135,480)
<b>Total comprehensive income for the period</b>	<b>1,673,174</b>	<b>1,611,692</b>	<b>3,265,569</b>	<b>2,798,095</b>
<b>Attributable to:</b>				
Shareholders of the Company	1,336,101	1,372,913	2,585,052	2,388,869
Non-controlling interest	337,073	238,779	680,517	409,226
	<b>1,673,174</b>	<b>1,611,692</b>	<b>3,265,569</b>	<b>2,798,095</b>

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Changes in Equity for the Six Months Ended at 30 June 2023 (Unaudited)**  
**(In Jordanian Dinar)**

	Paid - in Capital	Reserves Statutory    Voluntary	Changes in Foreign Exchange Rate	Retained Earnings	Total Shareholders Equity	Non- Controlling Interest	Total Equity
Balance at 1 January 2023	15,000,000	3,750,000    2,118,949	(2,772,950)	8,725,596	26,821,595	6,312,602	33,134,197
Company’s shareholders dividends paid (Note 4)	-	-    -	-	(1,500,000)	(1,500,000)	-	(1,500,000)
Non-controlling interest dividends paid	-	-    -	-	-	-	(85,500)	(85,500)
Total comprehensive income for the period	-	-    -	(23,061)	2,608,113	2,585,052	680,517	3,265,569
Balance at 30 June 2023	15,000,000	3,750,000    2,118,949	(2,796,011)	9,833,709	27,906,647	6,907,619	34,814,266
Balance at 1 January 2022	15,000,000	3,375,858    1,705,064	(2,507,710)	6,805,387	24,378,599	5,417,135	29,795,734
Company’s shareholders dividends paid	-	-    -	-	(1,200,000)	(1,200,000)	-	(1,200,000)
Non-controlling interest dividends paid	-	-    -	-	-	-	(55,575)	(55,575)
Total comprehensive income for the period	-	-    -	(135,480)	2,524,349	2,388,869	409,226	2,798,095
Balance at 30 June 2022	15,000,000	3,375,858    1,705,064	(2,643,190)	8,129,736	25,567,468	5,770,786	31,338,254

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"

**The Arab Pesticides & Veterinary Drugs Mfg. Co.  
Public Shareholding Company  
Interim Consolidated Statement of Cash Flows  
For the Six Months Ended at 30 June 2023 (Unaudited)**

(In Jordanian Dinar)

	30 June 2023	30 June 2022
<b>Operating activities</b>		
Profit before income tax	3,532,812	3,151,668
Depreciation	237,368	208,640
Share of profit from the associate company results	(165,187)	(141,423)
Provision for expected credit loss	50,000	200,000
<b>Changes in working capital</b>		
Checks under collection	(222,830)	(127,011)
Accounts receivable	(2,990,826)	(2,089,069)
Inventories	552,044	(1,067,249)
Other current assets	(232,045)	145,006
Accounts payable	(456,537)	1,356,249
Deferred checks	15,634	(17,972)
Other current liabilities	(355,930)	(522,350)
Income tax paid	(135,917)	(95,950)
<b>Net cash flows (used in) from operating activities</b>	<u>(171,414)</u>	<u>1,000,539</u>
<b>Investing activities</b>		
Property, plant and equipment	(291,417)	(507,751)
Investment in associate dividends	115,695	106,500
Project under construction	(1,193,904)	-
<b>Net cash flows used in investing activities</b>	<u>(1,369,626)</u>	<u>(401,251)</u>
<b>Financing activities</b>		
Credit facilities	925,546	1,336,412
Notes payable	294,302	58,254
Non-controlling interest dividends paid	(85,500)	(55,575)
Company's shareholders dividends paid	(1,500,000)	(1,200,000)
<b>Net cash flows (used in) from financing activities</b>	<u>(365,652)</u>	<u>139,091</u>
<b>Net changes in cash and cash equivalents</b>	(1,906,692)	738,379
Cash and cash equivalents, beginning of the year	4,009,268	3,725,670
<b>Cash and cash equivalents, end of the period</b>	<u><u>2,102,576</u></u>	<u><u>4,464,049</u></u>

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"



**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)**  
**30 June 2023**

**(In Jordanian Dinar)**

**1 . General**

The Arab Pesticides & Veterinary Drugs Mfg. Co. was established as a Limited Liability Company on 17 October 1991 and on 31/7/2005 the company changed to a Public Shareholding Company, and registered in the Hashemite Kingdom of Jordan under number (366), with the main objective of manufacturing of pesticides and veterinary medicines.

The Company shares are listed in Amman Stock Exchange – Jordan.

The condensed interim consolidated financial statements have been approved for issue by the Company's Board of Directors on 24 July 2023.

**2 . Summary of Significant Accounting Policies**

**Basis of Preparation**

The condensed interim consolidated financial statements of the Company have been prepared in accordance with International Accounting Standard number (34) "Interim Financial Reporting". They do not include all of the information required in annual financial statements in accordance with IFRSs, and should be read in conjunction with the consolidated financial statements of the Company for the year ended 31 December 2022.

The condensed interim consolidated financial statements have been prepared on a historical cost basis except for financial assets at fair value.

The condensed interim consolidated financial statements are presented in Jordanian Dinar which is the functional currency of the Company.

The accounting policies are consistent with those used in the previous period, except for the adoption of new and amended standards effective as at the beginning of the year.

**Principles of Consolidation**

The condensed interim consolidated financial statements comprise of the financial statements of the parent and its subsidiaries where the Company has the power to govern the financial and operating policies of the subsidiaries so as to obtain benefits from their activities. The financial statements of the subsidiaries are prepared for the same reporting year as the Company using consistent accounting policies. All balances, transactions, income, and expenses between the Company and its subsidiaries are eliminated.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Company obtains control, and continue to be consolidated until the date that such control ceases.

The results of operations of the subsidiaries are included in the consolidated statement of comprehensive income from the acquisition date which is the date on which control over subsidiary is transferred to the Company. The results of operation of the disposed subsidiary are included in the consolidated statement of comprehensive income to the disposal date which is the date on which the Company loses control over the subsidiary.

The following subsidiaries have been consolidated:

Company	Registration country	Ownership	Capital	Activity
Endmaj for Medical and Chemical Manufacturing Company	Jordan	100%	50,000	Manufacturing
Delta Sudia Manufacturing Company	KSA	55%	3,800,000	Manufacturing

### **Use of Estimates**

The preparation of the condensed interim consolidated financial statements requires management to make estimates and assumptions that affect the reported amount of the financial assets and liabilities and disclosure of contingent liabilities. These estimates and assumptions also affect the revenues and expenses and the resultant provisions and in particular, considerable judgment by management is required in the estimation of the amount and timing of future cash flows. Such estimates are necessarily based on assumptions about several factors involving varying degrees of judgment and uncertainty and actual results may differ resulting in future changes in such provisions.

Management believes that the estimates are reasonable and are as follows:

- Management reviews periodically the tangible assets in order to assess the depreciation for the year based on the useful life and future economic benefits. Any impairment is taken to the interim consolidated statement of profit or loss.
- The measurement of impairment losses under IFRS 9 requires judgment, in particular, the estimation of the amount and timing of future cash flows and collateral values when determining impairment losses and the assessment of a significant increase in credit risk. These estimates are driven by a number of factors, changes in which can result in different levels of allowances. Elements of the expected credit loss model that are considered accounting judgments and estimates include Probability of default (PD), Loss given default (LGD) and Exposure at default (EAD).
- Inventories are held at the lower of cost and net realizable value. When inventories become old or obsolete, an estimate is made of their net realizable value. For individually significant amounts this estimation is performed on an individual basis. Amounts which are not individually significant, but which are old or obsolete, are assessed collectively and a provision applied according to the inventory type and the degree of ageing or obsolescence, based on historical selling prices.

### **3 . Income Tax**

- The Company has settled its tax liability with the Income Tax Department up to 2018.
- The income tax returns for the years 2019, 2020, 2021 and 2022 has been filed with the Income Tax Department, but the Department has not reviewed the Company's records till the date of this report.
- The Income and National Contribution tax provision for the six months ended at 30 June 2023 was calculated in accordance with the Income Tax Law.

### **4 . Equity**

- The General Assembly approved in its meeting held in 2023 to distribute 10% cash dividends to its shareholders.
- The General Assembly approved to increase the Company's capital by JOD (1.5) million/share to become JOD (16.5) million/share through a private subscription at JOD (1) per share and with issuance premium of JOD (1) per share. The legal capital increase procedures has not been completed up to the date of the attached condensed interim consolidated financial statements.

## 5 . Fair Value of Financial instruments

The fair values of the financial assets and liabilities are not materially different from their carrying values as most of these items are either short-term in nature or re-priced frequently.

Financial assets and financial liabilities measured at fair value in the interim consolidated statement of financial position are grouped into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3: unobservable inputs for the asset or liability.

<u>30 June 2023</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at fair value through other comprehensive income	<u>-</u>	<u>-</u>	<u>237,090</u>	<u>237,090</u>
<u>31 December 2022</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at fair value through other comprehensive income	<u>-</u>	<u>-</u>	<u>237,090</u>	<u>237,090</u>

Financial assets included in level 3 are stated at cost less impairment charges, as the fair value of these assets cannot be measured reliably due to the lack of available active markets for identical assets.